Alerts will be sent to your verified email
Verify EmailGUFICBIO
|
Gufic Biosciences
|
Novartis India
|
Guj. Themis Biosyn
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
R&D as a % of Total Sales
|
1.28 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
16.89 % | 8.11 % | 34.65 % |
|
5yr average Equity Multiplier
|
2.16 | 2.72 | 1.29 |
|
5yr Average Asset Turnover Ratio
|
0.75 | 0.18 | 0.74 |
|
5yr Avg Net Profit Margin
|
10.24 % | 17.12 % | 35.51 % |
|
Price to Book
|
6.01 | 4.88 | 14.07 |
|
P/E
|
62.26 | 42.88 | 86.76 |
|
5yr Avg Cash Conversion Cycle
|
-15.25 Days | -23.33 Days | -112.39 Days |
|
Inventory Days
|
71.73 Days | 44.27 Days | 22.82 Days |
|
Days Receivable
|
106.89 Days | 38.18 Days | 70.51 Days |
|
Days Payable
|
179.29 Days | 124.28 Days | 130.88 Days |
|
5yr Average Interest Coverage Ratio
|
8.9 | 65.43 | 216.76 |
|
5yr Avg ROCE
|
17.89 % | 5.91 % | 45.66 % |
|
5yr Avg Operating Profit Margin
|
18.12 % | 15.15 % | 47.34 % |
|
5 yr average Debt to Equity
|
0.67 | 0.0 | 0.03 |
|
5yr CAGR Net Profit
|
-2.66 % | 37.01 % | 10.07 % |
|
5yr Average Return on Assets
|
7.7 % | 3.13 % | 26.69 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
72.5 % | 70.68 % | 70.86 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 5.44 % |
|
Change in Promoter Holding (3 Yrs)
|
-2.5 % | 0.0 | -4.13 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
2.6 % | 0.0 | 1.14 % |
|
Gufic Biosciences
|
Novartis India
|
Guj. Themis Biosyn
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
-
|